Pagano Monica B, Morton Suzy, Cohn Claudia S, Gross Sylvie, Kutner Jose, Lewin Antoine, McCullough Jeffrey, Schweitzer Irwin, Tinmouth Alan T, West Kamille, Stanworth Simon J
Laboratory Medicine, University of Washington Medical Center, Seattle, WA, USA.
NHS Blood and Transplant, University Hospitals Birmingham, Birmingham, UK.
Transfus Med Hemother. 2018 Oct;45(5):318-322. doi: 10.1159/000492629. Epub 2018 Aug 24.
Granulocyte transfusions are used to either treat or prevent life-threatening infections in neutropenic patients. Current evidence from clinical trials does not support or reject efficacy, nor guide practice.
A group of investigators have led the efforts to create an online registry to gather information on granulocyte transfusion practices from as broad a range of international settings. The data forms were adapted from an on-going study in England for electronic data management. Data is collected at the time of the request for granulocytes, weekly, at 28 days, and at 6 months. Information collected includes donor, granulocyte unit, patient and illness characteristics, and outcomes.
The PROspective GRanulocyte usage and outcomEs Survey (ProGrES) is currently open for data entry. Centres across the UK have collected data on 80 subjects. Five institutions from 4 countries (2 from the US, 1 each from Brazil, and national services in Canada and France) are in the process of joining the study. Other countries have expressed interest.
It is feasible to develop an international registry of granulocyte transfusions to characterise current practices and describe outcomes. This registry would provide a platform to explore the relationship between intervention and outcomes, and to generate evidence to inform granulocyte transfusion efficacy.
粒细胞输注用于治疗或预防中性粒细胞减少患者的危及生命的感染。目前来自临床试验的证据既不支持也不否定其疗效,也无法指导实践。
一组研究人员牵头创建了一个在线登记处,以收集来自广泛国际环境的粒细胞输注实践信息。数据表格改编自英国一项正在进行的电子数据管理研究。在请求粒细胞时、每周、28天和6个月时收集数据。收集的信息包括供体、粒细胞单位、患者和疾病特征以及结果。
前瞻性粒细胞使用和结果调查(ProGrES)目前已开放数据录入。英国各地的中心已收集了80名受试者的数据。来自4个国家的5个机构(美国2个、巴西1个、加拿大和法国的国家服务机构各1个)正在加入该研究。其他国家也表达了兴趣。
建立一个国际粒细胞输注登记处以描述当前实践并描述结果是可行的。该登记处将提供一个平台,以探索干预与结果之间的关系,并产生证据以告知粒细胞输注的疗效。